Eli Lilly does another #RNATherapeutic deal, this time with #Creyon. Oligo design and delivery. Sounds very complementary to the development of other modalities Lilly is working on, e.g. #ADARediting.
www.businesswire.com/news/home/20...
www.businesswire.com/news/home/20...
Creyon Bio and Lilly Enter into RNA-Targeted Oligo Therapy Development Collaboration
Creyon Bio, Inc. (“Creyon”) today announced a global licensing and multi-target research collaboration with Eli Lilly and Company (“Lilly”) focused on the di...
www.businesswire.com
April 29, 2025 at 3:25 PM
Eli Lilly does another #RNATherapeutic deal, this time with #Creyon. Oligo design and delivery. Sounds very complementary to the development of other modalities Lilly is working on, e.g. #ADARediting.
www.businesswire.com/news/home/20...
www.businesswire.com/news/home/20...
#ADARediting $PRQR quarterly update. All you need to know:
NTCP cholestatic disease candidate on track for Q2 CTA filing and Q4 readout (healthy volunteer, biomarker)
Cash runway into mid-2027.
finance.yahoo.com/news/proqr-a...
NTCP cholestatic disease candidate on track for Q2 CTA filing and Q4 readout (healthy volunteer, biomarker)
Cash runway into mid-2027.
finance.yahoo.com/news/proqr-a...
ProQR Announces First Quarter 2025 Operating and Financial Results
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Strengthened ...
finance.yahoo.com
May 8, 2025 at 1:42 PM
#ADARediting $PRQR quarterly update. All you need to know:
NTCP cholestatic disease candidate on track for Q2 CTA filing and Q4 readout (healthy volunteer, biomarker)
Cash runway into mid-2027.
finance.yahoo.com/news/proqr-a...
NTCP cholestatic disease candidate on track for Q2 CTA filing and Q4 readout (healthy volunteer, biomarker)
Cash runway into mid-2027.
finance.yahoo.com/news/proqr-a...